AI-Driven Systems Oncology: Modeling Tumor Evolution Through Multimodal Data Integration

[1]Dr. Aishwarya Pillai,[2]Dr. Danish Ali,[3]Mrs. Nisha Fernandes

[1]Associate Professor,Department of Pharmacology, Sree Gokulam Medical College, Thiruvananthapuram, India.Aishwaryapillai62@gmail.com

[2]Assistant Professor,Department of Radiology, Sree Gokulam Medical College, Thiruvananthapuram, India.Danishali47@gmail.com

[3]Assistant Professor,Department of Medical Biochemistry, Sree Gokulam Medical College, Thiruvananthapuram, India.Nishafernandes15@gmail.com

ABSTRACT:
Cancer remains one of the leading causes of morbidity and mortality worldwide despite remarkable advances in molecular diagnostics, targeted therapeutics, immunotherapy, and precision medicine. Tumor development is a dynamic systems-level process driven by genomic instability, epigenetic alterations, transcriptional regulation, metabolic reprogramming, immune interactions, and continuous adaptation within the tumor microenvironment. Understanding these complex biological processes requires computational approaches capable of integrating heterogeneous biomedical information across multiple molecular and clinical scales. Artificial intelligence (AI)-driven systems oncology has emerged as a transformative discipline that combines systems biology, multimodal learning, foundation AI models, graph neural networks, digital pathology, radiology, multi-omics, longitudinal clinical data, and mathematical modeling to characterize tumor evolution and support precision medicine. Machine learning, deep learning, transformer architectures, self-supervised learning, digital twins, agentic AI, and generative artificial intelligence now enable integration of radiological imaging, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable technologies, and electronic health records into unified patient-specific computational representations. These intelligent systems support diagnosis, prognostic prediction, biomarker discovery, therapeutic optimization, immunotherapy selection, adaptive treatment planning, and clinical decision support. Despite remarkable progress, important challenges remain regarding multimodal data harmonization, computational scalability, explainability, interoperability, regulatory validation, and ethical governance. This review provides a comprehensive overview of AI-driven systems oncology, highlighting computational principles, clinical applications, implementation challenges, and future perspectives for modeling tumor evolution through multimodal data integration.[1]

Keywords: Systems oncology, Artificial intelligence, Precision oncology, Tumor evolution, Multi-omics, Foundation models, Computational oncology, Digital pathology, Personalized medicine, Clinical decision support.

Received Date: 5 December 2025**; Accepted Date:** 15 December 2025**; Published Date:** 20 December 2025.

1.Introduction

Cancer is a dynamic biological system characterized by genomic instability, epigenetic dysregulation, transcriptional diversity, metabolic reprogramming, immune heterogeneity, and continuous interactions among malignant cells, stromal components, vascular networks, and the tumor microenvironment. Although remarkable advances in molecular medicine have improved diagnosis and treatment, patients with apparently similar pathological diagnoses frequently demonstrate markedly different therapeutic responses and clinical outcomes because of complex biological interactions occurring across multiple organizational levels.[2]

Modern oncology generates enormous quantities of heterogeneous biomedical information through radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory investigations, wearable biosensors, and electronic health records. While each modality provides valuable biological insight, isolated analysis of individual datasets fails to capture the dynamic systems-level behavior underlying tumor evolution.[3]

Artificial intelligence has emerged as one of the most transformative technologies in computational oncology by enabling automated interpretation of complex biomedical information. More recently, systems oncology has integrated AI with systems biology to model cancer as an interconnected biological network rather than a collection of isolated molecular abnormalities.[4]

The convergence of artificial intelligence, multimodal learning, systems biology, and computational modeling is therefore redefining precision oncology by enabling comprehensive characterization of tumor evolution through integration of heterogeneous biomedical information across the entire clinical workflow.[5]

2.Evolution of Systems Oncology

Traditional oncology largely focused on histopathological classification and individual molecular biomarkers to guide diagnosis and treatment. Although these approaches remain clinically valuable, they frequently fail to capture the remarkable biological complexity underlying cancer progression, metastasis, and therapeutic resistance.[6]

Systems biology introduced a new conceptual framework by representing biological processes as interconnected molecular networks involving genes, proteins, metabolites, immune responses, signaling pathways, and cellular communication. Machine learning subsequently enabled computational analysis of these highly complex biological interactions using increasingly sophisticated predictive models.

Recent advances in transformer architectures, graph neural networks, multimodal foundation models, digital twins, and agentic artificial intelligence have substantially expanded systems oncology by enabling comprehensive integration of imaging, pathology, multi-omics, laboratory investigations, and longitudinal clinical information into unified computational ecosystems.[7]

Today, AI-driven systems oncology provides an increasingly comprehensive framework for understanding tumor evolution while supporting adaptive precision medicine and individualized cancer management.[8]

3.Principles of AI-Driven Systems Oncology

Systems oncology differs fundamentally from conventional computational oncology because it models cancer as an interconnected biological system rather than focusing on isolated biomarkers or individual molecular pathways. Artificial intelligence integrates heterogeneous biomedical information into unified computational representations capable of describing dynamic biological interactions across multiple organizational levels.[9]

These systems incorporate radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, physiological monitoring, wearable technologies, and longitudinal clinical documentation. Graph neural networks model relationships among genes, proteins, signaling pathways, immune cells, metabolites, imaging phenotypes, and therapeutic targets.

Transformer architectures and multimodal foundation models further enable cross-modal reasoning by integrating complementary biological information into patient-specific computational embeddings capable of supporting diagnosis, prognostic prediction, therapeutic planning, and disease monitoring.[10]

4.Computational Architecture

Modern AI-driven systems oncology platforms consist of multiple interconnected computational layers responsible for multimodal data acquisition, preprocessing, biological network modeling, representation learning, predictive simulation, and intelligent clinical decision support.[11]

The acquisition layer collects radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory investigations, wearable sensor data, medication history, physiological monitoring, and electronic health records. Advanced preprocessing pipelines normalize imaging studies, harmonize molecular datasets, encode clinical narratives, and synchronize longitudinal patient information.

Multimodal transformer architectures generate generalized computational embeddings representing patient-specific biological states, whereas graph neural networks model interactions among molecular pathways, cellular

DOI: https://doi.org/10.65477/ijmdas.2025.v1.i6.16

communication networks, immune responses, therapeutic targets, and clinical outcomes.

Continuous integration of evolving biomedical information enables adaptive computational modeling throughout diagnosis, treatment, follow-up, and survivorship while supporting dynamic systems-level understanding of tumor biology.[12]

5.Artificial Intelligence and Biological Network Modeling

Artificial intelligence serves as the computational engine underlying systems oncology by enabling automated analysis of highly interconnected biological networks. Machine learning identifies statistical relationships among molecular biomarkers and clinical outcomes, whereas deep learning automatically extracts hierarchical representations from imaging, pathology, genomics, and physiological data.[13]

Graph neural networks have become particularly valuable because they naturally represent biological interaction networks involving genes, proteins, signaling pathways, immune responses, metabolites, vascular networks, and therapeutic targets. These graph-based computational models enable systems-level reasoning that extends beyond isolated molecular analyses.

Foundation AI models further strengthen biological modeling through generalized representation learning capable of integrating heterogeneous biomedical information while improving transferability across diverse cancer types and clinical environments.[14]

6.Multi-Omics Integration

Systems oncology depends upon comprehensive integration of genomics, transcriptomics, proteomics, metabolomics, epigenomics, immunomics, lipidomics, microbiomics, and single-cell sequencing into unified computational representations of tumor biology. Each molecular layer contributes complementary information regarding cellular function, therapeutic response, disease progression, and clinical outcomes.[15]

Artificial intelligence harmonizes these heterogeneous datasets through multimodal learning, graph neural networks, biological knowledge graphs, and transformer architectures that identify latent biological relationships across molecular pathways.

These integrated multi-omics representations substantially improve molecular subtype classification, biomarker discovery, therapeutic prediction, systems biology research, and individualized precision medicine while supporting comprehensive modeling of tumor evolution.[16]

7.Radiology, Digital Pathology, and Computational Phenotyping

Radiological imaging and digital pathology provide complementary phenotypic information describing tumor biology across multiple spatial scales. Medical imaging characterizes tumor morphology, vascularity, metabolism, anatomical relationships, and disease progression, whereas digital pathology provides microscopic characterization of tissue architecture, cellular morphology, immune infiltration, stromal remodeling, and angiogenesis.[17]

Artificial intelligence integrates radiomics with computational pathology through multimodal representation learning, enabling comprehensive computational phenotyping of tumors. Cross-modal transformer architectures identify relationships between macroscopic imaging phenotypes and microscopic tissue characteristics while improving diagnosis, prognostic prediction, molecular characterization, and therapeutic planning.

These integrated computational phenotypes substantially strengthen systems oncology by connecting anatomical imaging with cellular biology across multiple biological scales.[18]

8.Modeling Tumor Evolution

Tumor evolution represents one of the defining challenges of precision oncology because cancer continuously adapts through genetic mutation, clonal selection, immune escape, metabolic reprogramming, and therapeutic resistance. Systems oncology seeks to model these dynamic biological processes through continuous integration of multimodal biomedical information.[19]

DOI: https://doi.org/10.65477/ijmdas.2025.v1.i6.16

Artificial intelligence combines imaging, pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory investigations, wearable technologies, and longitudinal clinical records into adaptive computational models that simulate disease progression, metastatic dissemination, treatment response, recurrence, and survival.

These continuously evolving computational representations provide unprecedented opportunities for understanding cancer biology while supporting predictive precision medicine throughout the patient's clinical journey.[20]

9.Artificial Intelligence for Predictive Systems Oncology

One of the most important objectives of systems oncology is the ability to predict tumor behavior before clinically significant progression occurs. Artificial intelligence enables predictive systems oncology by integrating radiological imaging, digital pathology, multi-omics, laboratory biomarkers, physiological monitoring, treatment history, and longitudinal clinical information into continuously evolving computational models.[21]

Machine learning algorithms estimate tumor growth, metastatic dissemination, recurrence probability, progression-free survival, overall survival, treatment-related toxicity, and mechanisms of therapeutic resistance. Unlike conventional predictive models based on isolated biomarkers, systems-level computational models continuously incorporate newly acquired biomedical information, allowing prediction to evolve alongside changing tumor biology.

These adaptive computational systems enable clinicians to anticipate disease progression while supporting timely therapeutic intervention and individualized patient management.

10.Systems Oncology and Personalized Therapeutics

Personalized treatment planning represents one of the most significant applications of AI-driven systems oncology. Foundation AI models integrate molecular biology, imaging, pathology, laboratory investigations, treatment history, physiological monitoring, and patient-specific clinical characteristics into unified computational frameworks capable of supporting individualized therapeutic decision-making.[22]

Artificial intelligence predicts treatment response across chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, surgery, and multimodal treatment combinations while simultaneously estimating recurrence probability, progression-free survival, overall survival, treatment-related toxicity, and drug resistance.

Continuous integration of longitudinal patient information enables adaptive therapeutic recommendations that evolve throughout disease progression, supporting increasingly individualized precision medicine.

11.Tumor Microenvironment and Immunotherapy Modeling

The tumor microenvironment is a highly dynamic biological system composed of malignant cells, immune populations, fibroblasts, endothelial cells, extracellular matrix components, cytokines, and numerous signaling molecules that collectively influence disease progression and therapeutic response.

Artificial intelligence integrates radiological imaging, computational pathology, transcriptomics, immunomics, spatial biology, laboratory biomarkers, and clinical outcomes into systems-level computational representations of tumor–immune interactions.[23]

Graph neural networks model communication among immune cells, stromal components, signaling pathways, and tumor cells, allowing prediction of responsiveness to immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, bispecific antibodies, and adoptive cellular therapies.

These computational approaches provide increasingly comprehensive understanding of tumor ecosystem dynamics while facilitating personalized immunotherapeutic strategies.

12.Digital Twins and Adaptive Systems Biology

The convergence of systems oncology with digital twin technology is creating continuously evolving virtual patient ecosystems capable of integrating radiological imaging, digital pathology, multi-

DOI: https://doi.org/10.65477/ijmdas.2025.v1.i6.16

omics, laboratory biomarkers, wearable biosensors, treatment history, and longitudinal clinical information into adaptive computational models.[24]

Artificial intelligence continuously synchronizes these digital twins with biological patients, enabling simulation of tumor evolution, therapeutic response, toxicity, recurrence, metastatic progression, and survival before clinical intervention.

These adaptive computational ecosystems provide clinicians with opportunities to evaluate multiple therapeutic scenarios while supporting evidence-based precision medicine throughout diagnosis, treatment, follow-up, and survivorship.

13.Intelligent Clinical Decision Support

AI-driven systems oncology provides the computational foundation for next-generation clinical decision-support systems capable of integrating heterogeneous biomedical information into comprehensive patient-centered intelligence. Radiological imaging, pathology reports, genomic sequencing, laboratory investigations, medication history, wearable technologies, and electronic health records are continuously harmonized into unified computational representations.[25]

Interactive clinical dashboards present individualized diagnostic summaries, prognostic predictions, treatment recommendations, toxicity estimates, recurrence probabilities, survival forecasts, and adaptive therapeutic pathways while facilitating multidisciplinary collaboration among oncologists, radiologists, pathologists, surgeons, and molecular biologists.

These intelligent systems substantially reduce fragmentation of clinical information while improving evidence-based decision-making throughout the oncology workflow.

14.Explainable Artificial Intelligence and Clinical Translation

Although systems oncology models demonstrate remarkable predictive capabilities, successful clinical implementation requires transparency, interpretability, and clinician confidence. Explainable artificial intelligence (XAI) enables physicians to understand computational reasoning through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, and counterfactual reasoning that identify the biological variables contributing most strongly to computational predictions.[26]

Several implementation challenges remain. Systems oncology requires standardized multimodal datasets, secure computational infrastructure, interoperability across healthcare systems, robust biological validation, prospective multicenter evaluation, continuous monitoring for algorithmic bias, and strong cybersecurity measures.

Patient privacy, regulatory approval, equitable implementation, standardized computational reporting, and transparent governance frameworks will remain essential for responsible clinical translation.

15.Future Perspectives

Future AI-driven systems oncology will increasingly integrate multimodal foundation models, agentic artificial intelligence, digital twins, reinforcement learning, federated learning, liquid biopsy, spatial multi-omics, quantum computing, cloud-native healthcare infrastructure, and Internet of Medical Things (IoMT) technologies into unified computational ecosystems.[27]

These intelligent systems will continuously integrate molecular biology, imaging, pathology, laboratory medicine, wearable technologies, electronic health records, and real-world clinical outcomes while supporting adaptive therapeutic optimization, autonomous workflow coordination, personalized patient communication, and continuous evidence generation.

The evolution of systems oncology is expected to transform cancer management from reactive treatment toward predictive, preventive, adaptive, and precision-guided healthcare.

16.Discussion

AI-driven systems oncology represents one of the most significant paradigm shifts in computational cancer research by integrating multimodal biomedical information into comprehensive biological network models capable of describing tumor evolution across multiple organizational levels. Unlike conventional artificial intelligence systems that analyze isolated biomarkers, systems oncology captures dynamic interactions among molecular pathways, cellular populations, tissue architecture, imaging phenotypes, immune responses, and clinical outcomes.[28]

Applications spanning cancer diagnosis, biomarker discovery, precision therapeutics, immunotherapy, digital twins, computational pathology, radiogenomics, adaptive treatment planning, and intelligent clinical decision support demonstrate the extraordinary potential of systems oncology for improving individualized cancer care.

Nevertheless, continued advances in explainable artificial intelligence, computational infrastructure, interoperability, systems biology, regulatory science, cybersecurity, and multidisciplinary collaboration will remain essential for widespread clinical implementation.

17.Conclusion

AI-driven systems oncology is redefining precision medicine by integrating foundation AI models, multi-omics technologies, radiological imaging, digital pathology, laboratory biomarkers, wearable technologies, electronic health records, and longitudinal clinical intelligence into unified computational frameworks capable of modeling tumor evolution throughout the cancer care continuum.[29]

Advances in transformer architectures, graph neural networks, multimodal learning, digital twins, agentic artificial intelligence, federated learning, and generative artificial intelligence are expected to further strengthen systems-level computational reasoning while enabling increasingly accurate diagnosis, adaptive therapeutics, continuous disease monitoring, and evidence-based clinical decision-making.

Although important scientific, technical, ethical, and regulatory challenges remain, continued interdisciplinary collaboration among oncologists, molecular biologists, systems biologists, radiologists, pathologists, biomedical engineers, computer scientists, healthcare organizations, and regulatory agencies will accelerate responsible implementation of AI-driven systems oncology, ultimately improving patient outcomes and advancing the future of personalized cancer medicine worldwide.[30]

18.References

1.Synthia, F. et al. (2020) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.

2.Dr.Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312, DOI: https://doi.org/10.46121/pspc.52.4.13.

3.Dr.Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8

4.Zwanenburg, A. et al. (2023) ‘The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping’, Radiology, 308(2), e221422.

5.Lambin, P. et al. (2017) ‘Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis’, European Journal of Cancer, 48(4), pp. 441-446.

6.Dr.Ohmini Krishnamurthy Rajendran (Author), ANALYSIS OF DNA-DAMAGE AND CANCER-RELATED GENE EXPRESSION FOLLOWING SPACE-RADIATION EXPOSURE USING NASA OPEN SCIENCE DATA, Vol. 11 No. 5s (2025), International Journal of Advances in Signal and Image Sciences (IJASIS), https://xlescience.org/index.php/IJASIS/article/view/2054, DOI: https://doi.org/10.29284/jqgs5s28

7.Chaudhary, K. et al. (2021) ‘Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer’, Clinical Cancer Research, 27(5), pp. 1248-1259.

8.Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.

9.Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.

10.Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.

11.Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial, Nature, 616(7956), pp. 259-265.

12.Wei, L. et al. (2023) 'Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration', British Journal of Radiology, 96(1150), Article 20230211.

13.Boehm, K.M. et al. (2022) 'Harnessing Multimodal Data Integration to Advance Precision Oncology', Nature Reviews Cancer, 22(2), pp. 114–126.

14.Dr.Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4

15.Dr.Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7

16.Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.

17.Dr.Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5

18.Dr.Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5

19.Dr.Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38

20.Dr.Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14

21.Dr.Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12

22.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2

(2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18

23.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7

24.Dr.Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325, DOI: https://doi.org/10.46121/pspc.52.4.14

25.Dr.Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31

26.Dr.Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21

27.Dr.Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16

28.Dr.Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL Intelligence'DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33

29.Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.

30.Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.